» Articles » PMID: 38458755

Survey of Service Needs to Embed Genome Sequencing for Motor Neuron Disease in Neurology in the English National Health Service

Overview
Journal J Med Genet
Specialty Genetics
Date 2024 Mar 8
PMID 38458755
Authors
Affiliations
Soon will be listed here.
Abstract

All people with motor neuron disease (pwMND) in England are eligible for genome sequencing (GS), with panel-based testing. With the advent of genetically targeted MND treatments, and increasing demand for GS, it is important that clinicians have the knowledge and skills to support pwMND in making informed decisions around GS. We undertook an online survey of clinical genomic knowledge and genetic counselling skills in English clinicians who see pwMND. There were 245 respondents to the survey (160 neurology clinicians and 85 genetic clinicians). Neurology clinicians reported multiple, overlapping barriers to offering pwMND GS. Lack of time to discuss GS in clinic and lack of training in genetics were reported. Neurology clinicians scored significantly less well on self-rated genomic knowledge and genetic counselling skills than genetic clinicians. The majority of neurology clinicians reported that they do not have adequate educational or patient information resources to support GS discussions. We identify low levels of genomic knowledge and skills in the neurology workforce. This may impede access to GS and precision medicine for pwMND.

Citing Articles

Genetic testing for monogenic forms of motor neuron disease/amyotrophic lateral sclerosis in unaffected family members.

Howard J, Chaouch A, Douglas A, MacLeod R, Roggenbuck J, McNeill A Eur J Hum Genet. 2024; 33(1):7-13.

PMID: 39501102 PMC: 11711763. DOI: 10.1038/s41431-024-01718-4.

References
1.
Salmon K, Kiernan M, Kim S, Andersen P, Chio A, van den Berg L . The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain. 2022; 145(4):1207-1210. PMC: 9129091. DOI: 10.1093/brain/awab472. View

2.
Lemke A, Amendola L, Kuchta K, Dunnenberger H, Thompson J, Johnson C . Primary Care Physician Experiences with Integrated Population-Scale Genetic Testing: A Mixed-Methods Assessment. J Pers Med. 2020; 10(4). PMC: 7720124. DOI: 10.3390/jpm10040165. View

3.
Roggenbuck J, Eubank B, Wright J, Harms M, Kolb S . Evidence-based consensus guidelines for ALS genetic testing and counseling. Ann Clin Transl Neurol. 2023; 10(11):2074-2091. PMC: 10646996. DOI: 10.1002/acn3.51895. View

4.
Vajda A, McLaughlin R, Heverin M, Thorpe O, Abrahams S, Al-Chalabi A . Genetic testing in ALS: A survey of current practices. Neurology. 2017; 88(10):991-999. PMC: 5333513. DOI: 10.1212/WNL.0000000000003686. View

5.
Miller T, Cudkowicz M, Shaw P, Andersen P, Atassi N, Bucelli R . Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS. N Engl J Med. 2020; 383(2):109-119. DOI: 10.1056/NEJMoa2003715. View